Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 known ✓ | Q9HC29 | 1/20 | 0.38 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 2/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10702292 | 0.80 | TSHR (0.50) | TSHRKDM4ERAB9AALDH1A1TDP1 | |
| SCHEMBL28056036 | 0.71 | TSHR (0.68) | TSHRKDM4ERAB9AALDH1A1TDP1 | |
| SCHEMBL5547042 | 0.71 | TDP1 (0.52) | TSHRKDM4ERAB9AALDH1A1TDP1 | |
| Arsanilic Acid SCHEMBL31473000 | 0.66 | CA4 (0.56) | TSHRKDM4ERAB9AALDH1A1TDP1 | |
| SCHEMBL886902 | 0.63 | CYP2C19 (0.53) | TSHRKDM4ERAB9AALDH1A1TDP1 | |
| Arsanilic Acid SCHEMBL160507 | 0.62 | KDM4E (1.00) | TSHRKDM4ERAB9AALDH1A1TDP1 | |
| Arsanilic Acid SCHEMBL4837583 | 0.62 | KDM4E (1.00) | TSHRKDM4ERAB9AALDH1A1TDP1 | |
| SCHEMBL1533978 | 0.62 | TDP1 (0.46) | TSHRALDH1A1TDP1CYP3A4PARP10 | |
| SCHEMBL15384472 | 0.61 | — | — | |
| SCHEMBL8300008 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2018858-A1 | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic trioxide | Polarx Biopharmaceuticals, Inc. (US) | 2009-01-28 | — | — | EP | disclosed |
| US-7205001-B2 | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds | POLARX BIOPHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7179493-B2 | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds | POLARX BIOPHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7163703-B2 | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds | POLARX BIOPHARMACEUTICALS, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-7132116-B2 | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds | POLARX BIOPHARMACEUTICALS INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1621077-A1 | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds | Polarx Biopharmaceuticals, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050191367-A1 | Compositions and methods for the treatment of Primary and metastatic neoplastic diseases using arsenic compounds | POLARX BIOPHARMACEUTICALS, INC. | 2005-09-01 | — | — | US | disclosed |
| US-20050100611-A1 | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds | POLARX BIOPHARMACEUTICALS, INC. | 2005-05-12 | — | — | US | disclosed |
| US-6875451-B2 | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds | POLARX BIOPHARMACEUTICALS INC. (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1466607-A1 | Compositions for the treatment of primary and metastatic neoplastic diseases using arsenic compounds in combination with all-trans retinoic acid | Polarx Biopharmaceuticals, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1419778-A1 | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds | Polarx Biopharmaceuticals, Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20040047916-A1 | Compositions and methods for the treatme of primary and metastatic neoplastic disea using arsenic compounds | POLARX BIOPHARMACEUTICALS, INC. | 2004-03-11 | — | — | US | disclosed |
| EP-1391206-A1 | Pharmaceutical compositions comprising arsenic for the treatment of lymphoma | Polarx Biopharmaceuticals, Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1378240-A2 | Pharmaceutical compositions comprising arsenic for the treatment of multiple myeloma | Polarx Biopharmaceuticals, Inc. (US) | 2004-01-07 | — | — | EP | disclosed |
| EP-1378241-A1 | Pharmaceutical compositions comprising arsenic for the treatment of melanoma | Polarx Biopharmaceuticals, Inc. (US) | 2004-01-07 | — | — | EP | disclosed |
| EP-1374875-A2 | Pharmaceutical compositons comprising arsenic for the treatment of myelodysplastic syndrome | Polarx Biopharmaceuticals, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20020183385-A1 | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds | POLARX BIOPHARMACEUTICALS, INC. | 2002-12-05 | — | — | US | disclosed |
| EP-1022951-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRIMARY AND METASTATIC NEOPLASTIC DISEASES USING ARSENIC COMPOUNDS | POLARX BIOPHARMACEUTICALS INC (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1022951-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRIMARY AND METASTATIC NEOPLASTIC DISEASES USING ARSENIC COMPOUNDS | Polarx Biopharmaceuticals, Inc. (US) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999018798-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRIMARY AND METASTATIC NEOPLASTIC DISEASES USING ARSENIC COMPOUNDS | POLARX BIOPHARMACEUTICALS, INC. (US) | 1999-04-22 | — | — | WO | disclosed |